Elisabeth Paietta, Kathryn G Roberts, Victoria Wang, Zhaohui Gu, Georgina A N Buck, Deqing Pei, Cheng Cheng, Ross L Levine, Omar Abdel-Wahab, Zhongshan Cheng, Gang Wu, Chunxu Qu, Lei Shi, Stanley Pounds, Cheryl L Willman, Richard Harvey, Janis Racevskis, Jan Barinka, Yanming Zhang, Gordon W Dewald, Rhett P Ketterling, David Alejos, Hillard M Lazarus, Selina M Luger, Letizia Foroni, Bela Patel, Adele K Fielding, Ari Melnick, David I Marks, Anthony V Moorman, Peter H Wiernik, Jacob M Rowe, Martin S Tallman, Anthony H Goldstone, Charles G Mullighan, Mark R Litzow
Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1- B-ALL (aged 14 to 65 years). Although 93% of patients achieved remission, 41% relapsed at a median of 13 months (range, 28 days to 12 years). Five-year overall survival (OS) was 42% (95% confidence interval, 39, 44). Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of 282 patient samples, of which 264 were eligible for trial, accounting for 64...
September 16, 2021: Blood